Pfizer (PFE)
(Delayed Data from NYSE)
$28.86 USD
+0.41 (1.44%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $28.97 +0.11 (0.38%) 6:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.86 USD
+0.41 (1.44%)
Updated Oct 28, 2024 04:00 PM ET
After-Market: $28.97 +0.11 (0.38%) 6:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
The Zacks Analyst Blog Highlights: Pfizer, Johnson & Johnson, Delta Air Lines, Southwest Airlines and United Airlines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Johnson & Johnson, Delta Air Lines, Southwest Airlines and United Airlines
The Zacks Analyst Blog Highlights: JPMorgan, Verizon, Chevron, Pfizer and QUALCOMM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, Verizon, Chevron, Pfizer and QUALCOMM
Top Research Reports for JPMorgan, Verizon & Chevron
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Verizon Communications (VZ), and Chevron (CVX).
CDC's New Guidance Makes the Skyline Sunnier for U.S. Airlines
by Maharathi Basu
CDC's latest travel manual provides a further impetus to the U.S. airline stocks like Delta (DAL), Southwest Airlines (LUV) and American Airlines (AA), which are scaling an outstanding graph on the bourses this year.
SpringWorks (SWTX) Begins Dosing in Multiple Myeloma Study
by Zacks Equity Research
SpringWorks (SWTX) doses the first patient in a phase Ib study evaluating nirogacestat in combination with teclistamab for the treatment of relapsed or refractory multiple myeloma.
AbbVie's (ABBV) Rinvoq Dermatitis sNDA Review Gets Delayed
by Zacks Equity Research
The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in atopic dermatitis by three months.
J&J (JNJ) Gets Full Charge of Emergent COVID-19 Vaccine Plant
by Zacks Equity Research
The U.S. government places J&J (JNJ) in charge of Emergent's Baltimore factory. The facility will cease production of AstraZeneca shots.
Exelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo
by Zacks Equity Research
Exelixis' (EXEL) partner Ipsen secures an approval from the regulatory body in Europe for the combination of Cabomteyx and Opdivo to treat first-line RCC.
Dow, Gibraltar Industries, Pfizer, BioNTech and Micron highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Dow, Gibraltar Industries, Pfizer, BioNTech and Micron highlighted as Zacks Bull and Bear of the Day
Pfizer (PFE)/BioNTech COVID-19 Vaccine 100% Effective in Teens
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) report 100% efficacy for their COVID-19 vaccine in teenagers aged 12 to 15.
Dow Dips, Other Markets Up for the Day; Micron (MU) Beats
by Mark Vickery
Micron Technologies (MU), a Zacks Rank #1 (Strong Buy) memory and data storage giant, posted a modest beat on both top and bottom lines in its fiscal Q2 earnings.
ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development as the outbreak worsens.
Merck's (MRK) Breast Cancer sBLA for Keytruda Gets CRL (Revised)
by Zacks Equity Research
FDA issues a complete response letter to Merck's (MRK) sBLA seeking label expansion of Keytruda as neoadjuvant and adjuvant treatment for patients with triple-negative breast cancer. A phase III study in this indication is ongoing.
Merck (MRK) Keytruda Gets CHMP Nod for First-Line Bladder Cancer
by Zacks Equity Research
Merck (MRK) is seeking approval for label expansion of Keytruda in Europe to include first-line treatment of certain patients with advanced or metastatic urothelial carcinoma.
Moderna ETFs to Gain on Positive 'Real-World' Study Data
by Sweta Jaiswal, FRM
Positive coronavirus vaccine progress by Moderna (MRNA) grabs investors' attention.
Merck's (MRK) Breast Cancer sBLA for Keytruda Gets CRL
by Zacks Equity Research
FDA issues a complete response letter to Merck's (MRK) sBLA seeking label expansion of Keytruda as neoadjuvant and adjuvant treatment for patients with triple-negative breast cancer. A phase III study in this indication is ongoing.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $36.62, marking a +1.02% move from the previous day.
Thermo Fisher (TMO) Launches Surveillance Tool for COVID-19
by Zacks Equity Research
The latest launch of surveillance solution is an extremely timely development by Thermo Fisher (TMO) and is expected to witness fast market adoption.
J&J's (JNJ) Pharma Unit & COVID-19 Vaccine Key to 2021 Growth
by Zacks Equity Research
J&J's (JNJ) Pharma unit is performing above-market levels, helped by new drugs and label expansion of blockbuster drugs, Imbruvica, Darzalex & Stelara. Its COVID-19 vaccine is expected to contribute to sales growth.
Bull of the Day: Owens and Minor (OMI)
by David Borun
This medical logistics company made big gains in 2020 - and is poised to keep heading higher.
Pfizer (PFE) Gets Unfavorable Votes from FDA Panel for Tanezumab
by Zacks Equity Research
Pfizer (PFE) and Eli Lilly receive FDA Joint Advisory Committee's vote results for tanezumab being developed for treating osteoarthritis pain. The committee voted 1 in favor and 19 against tanezumab.
The Zacks Analyst Blog Highlights: Pfizer, UnitedHealth Group, Centene Corp, Cigna Corp and AMN Healthcare Services
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, UnitedHealth Group, Centene Corp, Cigna Corp and AMN Healthcare Services
AstraZeneca (AZN) Reports New Efficacy Data on COVID-19 Vaccine
by Zacks Equity Research
AstraZeneca (AZN) reports new efficacy data for its COVID-19 vaccine in the Unites States following criticism for providing outdated data.
4 Stocks That Continue to Gain From Telehealth Offerings
by Zacks Equity Research
We take a sneak peek into four telehealth stocks that are well-poised for growth on their robust digital services suite.
Myovant's (MYOV) Data on Relugolix for Uterine Fibroids Positive
by Zacks Equity Research
Myovant (MYOV) and partner Pfizer report positive data from the phase III LIBERTY study evaluating relugolix combination therapy for treating women with uterine fibroids.